Cybin (CYBN) AI Stock Analysis

• Market Cap: $1.92M
• Dividend Yield: N/A
• Average Volume (3M): 0.00
• Price to Earnings (P/E): ―
• Beta (1Y): N/A
• Revenue Growth: N/A
• EPS Growth: 33.28%
• Country: CA
• Employees: 50
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.95
• Shares Outstanding: 49,894,130
• 10 Day Avg. Volume: 0
• 30 Day Avg. Volume: 0
• PEG Ratio: 0.16
• Price to Book (P/B): 7.14
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -16.39
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: 0.00
• Enterprise Value/Ebitda: 0.00
• 1Y Price Target: $62.00
• Price Target Upside: 44186.60% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 37 Underperform
• Price Target: ―

Cybin's stock score is significantly impacted by its lack of revenue and continuous financial losses, resulting in a low valuation score. While technical indicators are neutral, positive corporate events indicate potential for future growth. However, current financial challenges remain the dominant concern.

Cybin Business Overview & Revenue Model

Company Description

Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.

How the Company Makes Money

Cybin makes money through the development and commercialization of psychedelic-based therapeutics. The company's revenue streams primarily include partnerships and collaborations with research institutions and pharmaceutical companies, conducting clinical trials, and potentially licensing its proprietary drug formulations and delivery technologies. As Cybin progresses through clinical trials and moves towards regulatory approval, it may also generate income through milestone payments and eventual sales of approved drugs. Strategic partnerships and collaborations play a significant role in supporting Cybin's research initiatives, contributing to funding and resources for its development programs.

Cybin Financial Statement Overview

Summary

Cybin faces financial difficulties with no current revenue and persistent net losses. Despite a strong equity base and cash reserves, the lack of revenue and positive cash flow poses sustainability risks.

Income Statement

Cybin has been experiencing significant financial challenges, evident from the absence of revenue in recent periods and substantial net losses. The company reported a negative EBIT and EBITDA, indicating operational inefficiencies and high costs relative to its revenue base. Historically, there was some revenue in 2021, but it has since dropped to zero, highlighting a concerning trend in revenue generation.

Balance Sheet

The balance sheet shows a strong equity position with zero debt, suggesting a conservative capital structure. However, the lack of revenue is a significant concern. The equity ratio is high, showcasing reliance on equity rather than debt. The company maintains a healthy cash position, but sustained losses could erode this over time.

Cash Flow

Cash flow from operations is negative, reflecting ongoing operational cash burn. Although the company has raised substantial financing, the free cash flow remains negative, indicating cash outflows exceed inflows. This trend suggests potential liquidity issues if the cash burn continues without revenue improvement.

Breakdown	TTM	Dec 2025	Dec 2025	Dec 2024	Dec 2023	Dec 2022
Income Statement
Total Revenue	0.00	―	0.00	0.00	0.00	0.00
Gross Profit	-52.59K	―	0.00	-424.00K	-251.00K	-168.00K
EBITDA	-147.08M	―	-142.67M	-78.58M	-47.24M	-63.67M
Net Income	-122.93M	―	-113.14M	-78.08M	-47.49M	-67.63M
Balance Sheet
Total Assets	210.81M	―	258.62M	302.02M	53.90M	92.11M
Cash, Cash Equivalents and Short-Term Investments	118.69M	―	135.02M	208.99M	16.63M	64.03M
Total Debt	44.50M	―	0.00	291.00K	0.00	0.00
Total Liabilities	59.05M	―	21.42M	10.10M	5.66M	5.99M
Stockholders Equity	151.76M	―	237.20M	291.93M	48.23M	86.12M
Cash Flow
Free Cash Flow	-105.59M	―	-103.27M	-69.62M	-50.74M	-19.26M
Operating Cash Flow	-103.63M	―	-101.30M	-68.91M	-47.43M	-19.03M
Investing Cash Flow	-1.95M	―	-1.97M	6.92M	-3.31M	-1.19M
Financing Cash Flow	75.06M	―	20.20M	254.51M	13.56M	35.78M

Cybin Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MOOD	42 Neutral	C$5.69M	-6.75	-32.09%	―	-50.89%	-32.33%
CYBN	37 Underperform	$1.92M	-0.02	-53.20%	―	―	33.28%

Cybin Corporate Events

Cybin CEO to Speak at Milken Institute Global Conference on Medical Breakthroughs

Cybin announced that its CEO, Doug Drysdale, will participate in a panel discussion at the 28th Annual Milken Institute Global Conference, focusing on the global landscape and opportunities for medical breakthroughs. This participation highlights Cybin’s commitment to advancing mental healthcare and its role in the rapidly evolving field of neuropsychiatry, potentially impacting its industry positioning and stakeholder interests.

Spark’s Take on TSE:CYBN Stock

According to Spark, TipRanks’ AI Analyst, TSE:CYBN is a Underperform.

Cybin’s stock score is significantly impacted by its lack of revenue and continuous financial losses, resulting in a low valuation score. While technical indicators are neutral, positive corporate events indicate potential for future growth. However, current financial challenges remain the dominant concern.

To see Spark’s full report on TSE:CYBN stock, click here.

Cybin Expands Strategic Partnerships for Phase 3 MDD Treatment Trials

Cybin has announced new strategic clinical site partnerships to support its multinational Phase 3 program, PARADIGM, evaluating CYB003 for the adjunctive treatment of Major Depressive Disorder (MDD). These partnerships, now totaling 18 sites, aim to enhance operational efficiency and patient recruitment, potentially reducing the time to trial completion. The APPROACH study will include approximately 45 clinical sites, with the second Phase 3 study, EMBRACE, expected to begin in mid-2025. This initiative underscores Cybin’s commitment to addressing the global mental health crisis and improving patient outcomes through innovative treatments.

Spark’s Take on TSE:CYBN Stock

According to Spark, TipRanks’ AI Analyst, TSE:CYBN is a Underperform.

Cybin’s stock score is low due to significant financial challenges, including no revenue and continuous losses. While the technical analysis is neutral, the valuation is negatively impacted by poor financial performance. Positive corporate events, like strategic partnerships, offer potential for future growth, but the current financial struggles outweigh these developments.

To see Spark’s full report on TSE:CYBN stock, click here.

Cybin Partners with Osmind to Boost Commercial Readiness for Psychiatry Programs

Cybin has announced a strategic partnership with Osmind to accelerate the commercial preparation of its clinical-stage psychiatry programs. By leveraging Osmind’s extensive network of over 800 clinics and its point-of-care software, Cybin aims to enhance its operational infrastructure for the commercialization of its lead clinical programs, CYB003 and CYB004, targeting major depressive disorder and generalized anxiety disorder, respectively. This collaboration is expected to facilitate Cybin’s market penetration and support its mission to transform the treatment paradigm for mental health disorders, addressing the significant unmet needs in the mental health crisis.

Spark’s Take on TSE:CYBN Stock

According to Spark, TipRanks’ AI Analyst, TSE:CYBN is a Neutral.

Cybin’s overall score reflects its financial struggles with no revenue and sustained losses. While technical indicators are neutral, the company’s valuation is negatively impacted by its financial performance. However, the positive corporate event related to the PARADIGM program offers potential for future growth if the initiative succeeds.

To see Spark’s full report on TSE:CYBN stock, click here.

Cybin Accelerates PARADIGM Program for Depression Treatment

Cybin has launched strategic clinical site partnerships to accelerate its PARADIGM program, a multinational Phase 3 initiative evaluating CYB003 for treating major depressive disorder. This program includes multiple studies across over 40 sites in the U.S. and Europe, with a significant addressable market of over 300 million people. With a robust drug development team and Breakthrough Therapy Designation from the FDA, Cybin aims to shift depression treatment towards more intermittent therapies rather than daily dosing.